Christine Marie Utter sold $922k of PTCT
SVP, CHIEF ACCOUNTING OFFICER at PTC THERAPEUTICS, INC.. 17,800 shares at an average of $51.77, traded Dec 2, 2024, filed Dec 4, 2024.
Score components
- +15RoleOfficer
- +24Trade size$922k at market
- +10Share of holdings soldSold 32% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -6.7%, 3m +4.2%, 6m +2.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-028286, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 2, 2024 | MOption exercise Common Stock10b5-1 | +3,105 | $51.00 | $158k | 55,533 | Dec 4, 2024 |
| Dec 2, 2024 | SOpen-market sale Common Stock10b5-1 | -2,497 | $51.34 | $128k | 53,036 | Dec 4, 2024 |
| Dec 2, 2024 | SOpen-market sale Common Stock10b5-1 | -608 | $52.24 | $32k | 52,428 | Dec 4, 2024 |
| Dec 2, 2024 | MOption exercise Common Stock10b5-1 | +14,695 | $51.00 | $749k | 67,123 | Dec 4, 2024 |
| Dec 2, 2024 | SOpen-market sale Common Stock10b5-1 | -9,919 | $51.53 | $511k | 57,204 | Dec 4, 2024 |
| Dec 2, 2024 | SOpen-market sale Common Stock10b5-1 | -4,776 | $52.45 | $251k | 52,428 | Dec 4, 2024 |
| Dec 2, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -3,105 | $0.00 | $0 | 14,695 | Dec 4, 2024 |
| Dec 2, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -14,695 | $0.00 | $0 | 0 | Dec 4, 2024 |
Related signals
Other insiders at PTC THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 21Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $158k 2,500 shares | -0% | |
| 6Weak | PTC THERAPEUTICS, INC. | Mark Elliott Boulding EXEC. VP AND CLO | $133k 2,073 shares | -2% | |
| 27Weak | PTC THERAPEUTICS, INC. | Glenn Steele Jr Md Phd director | $782k 12,000 shares | -35% | |
| 28Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $1.3M 20,000 shares | -2% | |
| 20Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $1.4M 20,000 shares | -1% | |
| 0Weak | PTC THERAPEUTICS, INC. | Mark Elliott Boulding EXEC. VP AND CLO | $204k 2,813 shares | -3% | |
| 0Weak | PTC THERAPEUTICS, INC. | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | $222k 2,464 shares | -4% | |
| 33Weak | PTC THERAPEUTICS, INC. | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | $4.1M 46,774 shares | -77% | |
| 5Weak | PTC THERAPEUTICS, INC. | Mark Elliott Boulding EXEC. VP AND CLO | $432k 5,079 shares | -5% | |
| 21Weak | PTC THERAPEUTICS, INC. | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | $693k 8,130 shares | -13% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.